Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients

John C. Reneau, Dennis Asante, Holly van Houten, Lindsey R. Sangaralingham, Francis K. Buadi, Amir Lerman, Joerg Herrmann

Research output: Contribution to journalLetter

10 Scopus citations

Fingerprint Dive into the research topics of 'Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients'. Together they form a unique fingerprint.